Welcome to BiologicsBlog.com

Welcome to the Biologics Blog, which will track and analyze developments in intellectual property law related to biologic medical products as well as regulatory and legislative changes. Our impetus for starting the blog is the recent onset of regulatory activity and litigation under the Biologics Price Competition and Innovation Act of 2009 ("BPCIA"), which created a new regulatory and legal framework for biosimilar and interchangeable biologic products. The BPCIA regulatory and litigation pathway is just beginning to take shape and we plan to cover it on this blog. We also plan to track developments in biotech patent law more generally both in court decisions and AIA trial proceedings. For example, one of our first posts, The Trouble With Being Short, addresses recent case law on the patentability of short DNAs after the Association for Molecular Pathology v. Myriad.

We are excited to engage in this public conversation about the law concerning biologics and to update you on the developments impacting the biotech industry. We encourage you to participate. Please feel free to email us with any comments about what we write, suggestions for further posts, or anything else. Thank you for reading and we hope you enjoy the blog.